Actuate Therapeutics gets Nasdaq minimum bid price notice; 180 days to April 26, 2027 to regain $1.00

ACTUATE THERAPEUTICS, INC.

Nasdaq notice dated Oct 28, 2026: ACTU closing bid stayed below $1.00 for 30 consecutive business days, breaching Rule 5450(a)(1).
Compliance window runs 180 calendar days to April 26, 2027; requires 10 straight closes at $1.00 or more plus meeting other Global Market standards.
Common stock continues trading on the Nasdaq Global Market under ACTU; the notice has no immediate effect on listing.
Separate July 15, 2026 MVLS deficiency notice gives until January 11, 2027; a second 180-day bid-price period would require moving to the Nasdaq Capital Market.
Company says it is monitoring its bid price and weighing options, with no assurance it regains compliance or avoids delisting.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.